. Author manuscript; available in PMC: 2012 Oct 1.

Published in final edited form as: Cancer. 2011 Oct 1;117(19):4424–4438. doi: 10.1002/cncr.26073

Table 1.

Growth inhibition of DNA methylation inhibitors and HDAC inhibitors for Hey and SKOv3 ovarian cancer cells.

	Hey		SKOv3
Treatment	IC₅₀ (µM)	IC₇₅ (µM)	IC₅₀ (µM)	IC₇₅ (µM)
AZA	6.10	12.35	13.16	45.82
DAC	35.2	284.3	385.5	21501.1
SAHA	1.92	3.84	1.21	3.05
TSA	0.092	0.178	0.071	0.163
AZA+SAHA	3.52+0.80^*	7.53+1.72^*	6.11+0.36^*	15.38+0.91^*
AZA+TSA	4.04+0.046^*	7.99+0.091^*	7.53+0.025^*	17.39+0.057^*
DAC+SAHA	0.44+0.024^*	2.59+0.14^*	2.27+0.076^*	11.42+0.38^*
DAC+TSA	0.80+0.0022^*	3.91+0.011^*	3.93+0.011^*	14.55+0.040^*

For the combination treatments, we provide an estimate and 95% confidence interval for the second drug based on the experimental design, which set the dose of the second drug to be a constant ratio of the first drug’s dose.